Carfilzomib Improves Bone Metabolism in Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results of the CarMMa Study.

Although a clinically relevant reduction in CCL3 levels was evident at 8 and 10 months post-Kd initiation, the absolute changes in the biomarker levels did not reach statistical significance at any time point ( Table 2 , Figures S2 and S3 ).

also in 111,027 other papers